Brief: Tourmaline Bio Reports First Quarter 2025 Financial Results
02/05/2025 14:44
May 2 (Reuters) - Tourmaline Bio Inc TRML.O: TOURMALINE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS TOURMALINE BIO INC - HAS $275.3 MILLION CASH RUNWAY INTO H2 2027 TOURMALINE BIO INC: QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.89 Source text: ID:nGNX1qqpD5 Further company coverage: TRML.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy